{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015549","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.315689+00:00","generated_at":"2026-06-24T03:01:28.514862+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Terns Pharma Q2 net loss widens to $13.9M; cash runway into 2025","bullets":["Net loss of $13.9M ($0.55 per share) vs $10.7M ($0.43) in Q2 2021.","Cash and equivalents $139.8M as of June 30, down from $166.0M at Dec 31, 2021; expected to fund operations into 2025.","R&D expenses $8.7M (up from $6.0M); G&A $5.4M (up from $4.9M).","TERN-701 Phase 1 CML trial initiated in China; TERN-601 IND-enabling on track for Phase 1 obesity trial in 2023.","TERN-501 Phase 2a DUET NASH trial initiated; top-line data expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015549","json":"https://secwatch.observer/filing/0000950170-22-015549.json","markdown":"https://secwatch.observer/filing/0000950170-22-015549.md","text":"https://secwatch.observer/filing/0000950170-22-015549.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017022015549/0000950170-22-015549-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017022015549/tern-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:01:28.514862+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}